Bevacizumab (Avastin®) in therapy of tumors of a brain

A review of the literature on the outcome of the use of Вevacizumab (Avastin ®) - for brain tumors. Most published papers are devoted to the use of bevacizumab in recurrent and resistant forms of malignant gliomas in adults and a small number of dedicated use of the drug in the same situations in children and in primary chemoradiation therapy of gliomas in adults. As a result of Bevaсizumab achieved lengthening of life of patients without tumor progression, but the increase in survival was obtained only when using the drug in combination with other chemotherapeutic agents and radiation therapy as first-line treatment of the complex. Bevaсizumab demonstrated ability to reduce peritumoral edema, reducing the need for corticosteroids. Complications in the form of trombophlebitis, hemorrhage, hypertension, delayed wound healing and myelodepression observed relatively rarely, and usually are not fatal character. The findings suggest the advisability of further studies using Bevacizumab with chemoradiation therapy of primary malignant gliomas patients after operation.